Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00374699 | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | Samsung Medical CenterOTHER | 1 | Oct 14, 2009 | clinicaltrials |
| NCT00520637 | A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01) | completed | Phase 1 | 34 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 9, 2009 |
| NCT00006246 | Busulfan in Treating Children and Adolescents With Refractory CNS Cancer | completed | Phase 1 | 28 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 7, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00471367 | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00401739 | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | completed | Phase 1 | 40 | CSL LimitedINDUSTRY | 1 | Sep 16, 2009 | clinicaltrials |
| NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Sep 11, 2009 | clinicaltrials |
| NCT00147875 | Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 60 | University of CologneOTHER | 1 | Sep 7, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00955292 | Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 12 | Cylene PharmaceuticalsINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00955786 | Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 48 | Cylene PharmaceuticalsINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00759837 | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | completed | Phase 1 | 27 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 16, 2009 | clinicaltrials |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | completed | Phase 1 | 70 | BiogenINDUSTRY | 2 | Jul 14, 2009 | clinicaltrials |
| NCT00053105 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | TheradexINDUSTRY | 1 | Jul 7, 2009 | clinicaltrials |
| NCT00004086 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 9, 2009 | clinicaltrials |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | terminated | Phase 1 | 15 | BiogenINDUSTRY | 1 | Jun 5, 2009 | clinicaltrials |
| NCT00113724 | Study of TPI 287 in Patients With Advanced Malignancies | completed | Phase 1 | 48 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00070083 | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | completed | Phase 1 | — | British Columbia Cancer AgencyOTHER | 2 | Apr 7, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00452257 | A Study of Enzastaurin in Patients With Leukemia | completed | Phase 1 | 18 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 19, 2009 | clinicaltrials |
| NCT00533728 | Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | Biotec Pharmacon ASAINDUSTRY | 1 | Mar 4, 2009 | clinicaltrials |
| NCT00043420 | CPG 7909 in Patients With Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00821301 | Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma | unknown | Phase 1 | 30 | Immune ControlINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00807196 | Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 20 | Maisonneuve-Rosemont HospitalOTHER | 1 | Dec 11, 2008 | clinicaltrials |
| NCT00088101 | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors | completed | Phase 1 | 42 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Dec 4, 2008 | clinicaltrials |
| NCT00458250 | Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H | completed | Phase 1 | 10 | Tehran University of Medical SciencesOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | completed | Phase 1 | 4 | Memgen, LLCINDUSTRY | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | completed | Phase 1 | 21 | Agenus Inc.INDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | completed | Phase 1 | 9 | Memgen, LLCINDUSTRY | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00777530 | Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects | completed | Phase 1 | 48 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 23, 2008 | clinicaltrials |
| NCT00161590 | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma | completed | Phase 1 | — | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 22, 2008 | clinicaltrials |
| NCT00085904 | Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Oct 13, 2008 | clinicaltrials |
| NCT00222443 | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | completed | Phase 1 | 40 | University of OklahomaOTHER | 1 | Sep 22, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00347971 | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | completed | Phase 1 | 23 | ZymoGeneticsINDUSTRY | 1 | Sep 5, 2008 | clinicaltrials |
| NCT00538096 | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | withdrawn | Phase 1 | 18 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2009source: clinicaltrials